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was signiflcsntly smaller I” H vs N hearts (14+4% and 45+4%, p=.OOOO). Conclusion: with Killip Class II or Ill. The Table shows the medications administered during the first 24 
This study shows that hypothermic therapy initiated late during ischemia and continuing hours of presentation and at discharge. 
for several hours of rep significantly improves reflow and reduces macroscopic zones of Conclusion: Despite available data showing the benefit of proven medical therapies for 
no-reflow and hemorrhage in this model, suggesting protection of the microvasculature the treatment of patients with acute coronary syndromes and congestive head failure, 
by reducing repeiiusion injury. As reflow is a predictor of outcome, this intervention may except for aspirin, many of these medications continue to be underutilized especially in 
have important clinical implications. high-risk patients. 
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1171-106 Early Short-Term Use of Atorvastatin and Pravastatin in 
Patients With Non-ST Elevation Acute Coronary 
Syndrome: Changes of Hemostatic Parameters 
Ekaterlna Pokrovskaya, Nikolai Vaulln, Oleg Averkov. Natalia Slavina. Nikolai 
Gratsiansky. Institute of Physico-Chemical Medicine, Moskva, Russian Federation 
Background. Whether statins rapidly (in 1-2 weeks) and similarly affect hemostatic 
parameters in patients with non-ST elevation acute coronary syndrome (NSTEACS) is 
unknown. 
Methods: Ninety aspirin and heparin treated patients with NSTEACS were randomized 
~24 hours from pain onset to open pravastatin 40 mglday (n=31), atorvastatin 10 mgiday 
(n=30) or atorvastatin 40 mglday (n=29). Plasma thrombin-antithrombin complex (TAT), 
prothrombin fragments I+2 (Fl+2). D-dimer and van Willebrand factor (vWF) were mea- 
sured by ELISA at baseline, on days 7, 14. Results were compared with data from con- 
trols (n=l8) of another randomized study on similarly treated patients. 
Results: In all treatment groups levels of low-density lipoprotein cholesterol (LDLC) were 
lowered by days 7 (pcO,Ol) and 14 (p<O,Ol vs. baseline and for both atolvastatin groups 
vs. day 7). In pravastatin group levels of TAT and Fl+2 decreased, while vWF level 
increased (table). In atorvastatin groups levels of TAT and F 1+2 increased while level of 
vWF decreased Contrary to pravastatin group changes in atorvastatin groups more 
resembled those in controls not receiving lipid lowering drugs. There was slight negative 
correlation between changes of LDLC and TAT levels. No consistent changes of D-dimer 
occurred. 
Conclusion : Early use of pravastatin and atorvastatin in patients with NSTEACS was 
associated with divergent changes of some hemostatic paramebxs. 
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Thlbaud Dam& Anissa Bouzamondo, Gilles Montalescot, Philippe Lechat, Pitie 
Saleptriere Hospital, Pans, France 
Background: In acute coronary syndrome without ST elevation (ACS), there is conflict- 
ing evidence regarding the efficacy of low molecular weight heparin (LMWH) versus 
unfractionnated heparin (UFH). We performed a meta-analysis of trials comparing the 
class of LMWH versus UFH on the combined criteria of Death or Myocardial Infarction (D 
or MI) I” ACS. 
Methods: Randomised trials were identified using Medline and Cochrane database. 
Pooled Relative Risk was calculated with published data. Seven trials Including 15998 
patients fulfilled the inclusion criteria (Gudinkel, FRIC, FRISC, FRISC II, ESSENCE, TIMI 
11 B, FRAXIS). 
Results: M&a-analysis of five trials (Gurfinkel, FRIC. ESSENCE, TIMI llB, FRAXIS), 
including 12169 patients demonstrated superiority of LMWH versus UFH to reduce D or 
Ml during the acute phase (6-8days) [RR=0.83; 95%Cl(O.70-0.99); p=O.O42]. Heteroge- 
neity test was non significant (p=O.47) but subgroup analysis according lo the type of 
LMWH, showed that amplitute of benefit was highest with enoxaparin IRRz0.78; (0.62. 
0.96); p=O.O2] compared to dalteparin [R&1.09; (0.65.1.82)] or nadroparin (RRz0.92; 
(0.62-1.37)]. M&-analysis of long term LMWH administration trials (FRIC, FRISC, 
FRISCII, TIMIllB, FRAXIS) showed that no additional benefit [RR=O.SE; (0.82-1.16); 
p=O.78] was obtained when considering only events occurring after the acute phase. 
During the acute phase, no significant difference was observed for major bleedings 
[RR=l.Ol; (0.81.1.26)]. However minor bleedings were significantly Increased by LMWH 
[RR=l.96; (1.65.2,61); piO.OOl]. Prolonged administration significantly increased the 
major bleeding rate [RR=2.27; (1.63-3.18); p<O.OOl)]. Conclusion: When considering 
ischemlc events during the first week of ACS, there is a signlflcant favorable class effect 
for LMWH compared to UFH. However, prolonged LMWH treatment increases major 
bleedings without significant additional benefit on ischemic events. 
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Patients With and Without Heart Failure Presenting With 
Acute Coronary Syndromes: Insights From the 
PURSUIT Study 
Monvadi B. Srichai, Robert A. Harrington, Judith S. Hochman, Penny L. Houghtaling, 
Eric J. Velazquez, A. Michael Lincoff, Maarten L. Sirnoons, Wael A. Jaber, The 
Cleveland Clinic Foundation, Cleveland, OH, Duke University Medical Center, Durham, 
NC 
Background: Several medical interventions have been proven in the last two decades to 
improve the prognosis of patients with coronary artery disease and congestive heart fail- 
ure. We evaluated the rate of utilization of proven medical therapies in major national and 
international medical centers participating in the PURSUIT trial. 
Methods: We analyzed 9419 patients who were enrolled in the PURSUIT trial between 
November 1995 and January 1997. We assessed the medication usage at the time of 
randomization and at discharge for patients presenting with and without symptoms of 
hearl failure on presentation. 
Results: 8558 patients presented with Killlp class I and 861 patients were diagnosed 
1171-109 Adherence to Secondary Prevention Therapies 
Following Acute Coronary Syndromes: One-Year 
Results From the Canadian Acute Coronary Syndrome 
Registry 
Andrew T. Yan, Shaun G. Goodman, Mary Tan, David Fitch&t, Chi-Ming Chow, Anatoly 
Langer, Canadian ACS Registry Investigators, University of Toronto and Canadian Heart 
Research Centre. Toronto. ON, Canada 
Background: Clinical trials have clearly established the role of effective pharmacothera- 
pies in the secondary prevention of acute coronary syndrome (ACS) However, there are 
limited data regarding the longer-term adherence to these therapies after discharge. 
Methods: The ACS Registry is a prospective Canadian observational study of 5312 
patients with suspected ACS from 51 centres I” 9 provinces. A final diagnosis of ACS 
was dstermined in 4627 patients (27% Q wave myocardial infarctjon, 31% non-Q myo- 
cardial infarction, 41% unstable angina). Discharge medication use was recorded by 
treating physicians. Follow-up medication use (determlned by standardized telephone 
interview) was available for 3844 one-year survivors (8.8% unavailable). We compared 
the rates of medication use at discharge and at 1 year. 
Results: Medication use in 3844 patients at discharge and at l-year follow-up were as 
follows: 
